News

Applications are being accepted for the Cystic Fibrosis Foundation‘s 2023 CFF Impact Grant program, which funds projects or programs to improve the lives of those with cystic fibrosis (CF) or their families. “The best ideas come from personal experience, and no one knows the ins and outs…

AP-PA02, an experimental phage therapy for people with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa respiratory infections, was well tolerated and reduced the bacterial load in the lungs, according to top-line results from a Phase 1b/2a trial. High doses of AP-PA02 were associated with durable reductions in bacterial load in the SWARM-Pa study. Pharmacokinetics data,…

An antibiotic susceptibility kit, called AtbFinder, helped doctors choose effective antibiotics against lung infection caused by hard-to-treat Pseudomonas aeruginosa in four hours, and this led to fewer hospital stays, less use of systemic antibiotics, and better outcomes for people with cystic fibrosis (CF), according to a small…

The IRT test, commonly used for screening newborn for cystic fibrosis (CF), is most accurate when performed between three to six days after at-term babies have been born, a study shows. A repeat IRT test may be diagnostically useful in certain cases, such as for very pre-term babies,…

Trikafta increased the production of the faulty CFTR protein in cystic fibrosis (CF) patients, but it remained in an immature state, a study suggests. These findings may shed light on the wide variability in response rates in CF patients and caution that immature CFTR protein may prevent sustained…

Exposure to traffic-related air pollution is an important predictor of early lung function decline in children and adolescents with cystic fibrosis (CF), a study has found. Community deprivation — reflecting poverty, housing, income, education, and health insurance coverage — was also a significant predictor of this decline in young…

Unique global changes in gene activity and protein production were linked to different types of mutations in the CFTR gene, the underlying cause of cystic fibrosis (CF), a cell-based study has revealed. These changes were most likely due to the cell’s attempt to cope with global gene activity changes…

CDX-7108, an oral therapy being developed by Codexis for exocrine pancreatic insufficiency (EPI) — which is common in people with cystic fibrosis (CF) — may safely improve fat absorption, according to interim data from an ongoing Phase 1 clinical trial. The trial, sponsored by Nestlé Health Science,…

A single round of airway clearance therapy (ACT) led to immediate improvements in some lung function tests for cystic fibrosis (CF) patients, a study found. However, mucus that plugs up the airways wasn’t cleared by a single treatment. Overall findings from the study highlight “the potential remaining importance of…

BX004, BiomX’s experimental phage cocktail — a treatment that uses certain viruses to kill disease-causing microorganisms — was seen to reduce the number of Pseudomonas aeruginosa bacteria present in the lungs of people with cystic fibrosis (CF) in the first part of a small trial. The nebulized…